Market research
STX.LSE Shield Therapeutics plc
LSE GBP Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 48M
- P/E ratio
- Not available
- Analyst target
- 16.667
- Dividend yield
- Not available
- Beta
- 1.77
Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- GB00BYV81293
- Market cap
- 48M
- P/E ratio
- Not available
- Analyst target
- 16.667
- Dividend yield
- Not available
- Beta
- 1.77
About
About Shield Therapeutics plc
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru (ferric maltol), a non-salt based oral therapy for patients to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the STX.LSE discussion.
5 years, 5 months ago
Shield Therapeutics plc is currently in a long term downtrend where the price is trading 27.8% below its 200 day moving average.
From a valuation standpoint, the stock is 98.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.9.
Based on the above factors, Shield Therapeutics plc gets an overall score of 1/5.